Hong Kong Institute of Allergy and Hong Kong Society for Paediatric Immunology Allergy & Infectious Diseases joint consensus statement 2018 on vaccination in egg-allergic patients

Gilbert T Chua, Philip H Li, Marco HK Ho, Ellen Lai, Vivian Ngai, Felix YS Yau, Mike YW Kwan, TF Leung, TH Lee

Abstract
Vaccination of egg-allergic individuals has been a historical concern, particularly for influenza and measles-mumps-rubella-varicella vaccines that are developed in chicken egg embryos or chicken cell fibroblasts. The egg proteins in these vaccines were believed to trigger an immediate allergic reaction in egg-allergic individuals. However, recently published international guidelines have updated their recommendations and now state that these vaccines can be safely administered to egg-allergic individuals. This joint consensus statement by the Hong Kong Institute of Allergy and the Hong Kong Society for Paediatric Immunology Allergy & Infectious Diseases summarises the updates and provides recommendations for local general practitioners and paediatricians.

Background
Vaccination is an important and effective method to develop active immunity against certain pathogens. It helps to prevent or reduce the risks of developing certain infectious diseases as well as moderating disease severity. However, the administration of certain vaccines, including influenza, measles-mumps-rubella (MMR), measles-mumps-rubella-varicella (MMR-V) and yellow fever vaccines, has historically been relatively, if not absolutely, contraindicated in egg-allergic individuals. This is because these vaccines are developed in chicken egg embryos or chicken cell fibroblasts, raising the concern that egg proteins (notably ovalbumin) in these vaccines may trigger an immediate allergic reaction in egg-allergic individuals. As a result, previous vaccination guidelines and vaccine product information have recommended avoidance of influenza and MMR or MMR-V vaccines in individuals with a history of anaphylactic reaction to egg exposure.

Local epidemiological studies have shown that 0.4%-0.7% of Hong Kong children were reported by their parents to have had an adverse reaction to intake of a hen's egg. No local data for the adult population are available. However, it is important to differentiate between adverse reactions and genuine egg allergy, especially when deciding the need for vaccine avoidance. A recent United Kingdom multicentre study found that more than a third of patients with suspected egg allergy who were referred to a tertiary allergy centre for vaccination were not actually egg allergic, and all were vaccinated successfully. Despite the paucity of evidence, there remains some concern that administration of vaccines that could contain egg proteins, notably ovalbumin, might cause allergic reactions in egg-allergic subjects. The Centre for Health Protection recommends that mildly egg-allergic individuals can safely receive inactivated influenza vaccine in a primary care setting. However,
those with confirmed or suspected egg allergy who have experienced severe reactions should be seen by an allergist/immunologist for evaluation of their egg allergy prior to administration of inactivated influenza vaccine.4

Recently published international guidelines have updated their recommendations regarding the administration of vaccines to egg-allergic individuals. This joint consensus statement by the Hong Kong Institute of Allergy and the Hong Kong Society for Paediatric Immunology Allergy & Infectious Diseases summarises recent updates and provides recommendations for local general practitioners and paediatricians. For practical reasons, this guideline will only cover influenza and MMR/MMR-V vaccines.

Yellow fever vaccine is less commonly administered and is commonly propagated in hens’ eggs. Specialist evaluation is recommended prior to vaccination for evaluation of suspected egg allergies with vaccine skin testing or consideration for desensitisation.3 An egg-free yellow fever formulation is available as an alternative. The Q fever vaccine is not available in Hong Kong and therefore is not covered in this guideline.

Influenza vaccine

Influenza vaccination is well known to be effective in preventing infections caused by influenza viruses and in reducing the risk of developing complications. We reviewed the product information recommendations of Vaxigrip (Sanofi Pasteur SA, Lyon, France), Fluarix Tetra (GlaxoSmithKline Biologicals, Dresden, Germany), and FluQuadri (Sanofi Pasteur SA, Lyon, France). All recommended that patients with egg or chicken protein hypersensitivity are contra-indicated to receive their vaccines. However, upon direct communication with the respective pharmaceutical companies, all of them were reported to contain <0.1 µg/mL of ovalbumin in their vaccines. Therefore, we disagree with their recommendations.

Moneret-Vautrin et al5 reported that only 1% of egg-allergic patients would develop allergic reactions at a threshold as low as 1 mg. As the quantity of ovalbumin in influenza vaccines is ≤1 µg/dose, such a level of egg protein in influenza vaccines is very unlikely to trigger an allergic response in this group of patients. Thus, despite the product information recommendations and the trace amounts of ovalbumin present in these influenza vaccines, they should be safe for egg-allergic individuals, including those with a history of anaphylaxis to egg proteins.

Our view is supported by numerous international guidelines on administration of influenza vaccines to egg-allergic individuals, summarised in the Table.6-12

Measles-mumps-rubella and measles-mumps-rubella-varicella vaccines

The MMR and MMR-V vaccines are safe and effective in preventing mumps, measles, rubella, and varicella. The vaccination schedule in Hong Kong recommends that the first dose be administered at age 1 year and the second dose at Primary 1 (age 5-6 years).13 We reviewed the product information recommendations of two MMR-V vaccines available in Hong Kong: Priorix-Tetra (GlaxoSmithKline plc [GSK], Brentford, UK) and ProQuad (Merck & Co, Inc, Kenilworth [NJ], US). The manufacturers of both of these products recommend that patients with severe allergic reactions after egg ingestion should take extra precaution when receiving the vaccines. However, in direct communication with the manufacturers, GSK replied that Priorix-Tetra may contain traces of egg protein but the amount is not measured in the final product. In contrast, Merck replied that internal analysis was done for ProQuad for its egg protein content; however, they refused to disclose the information as they consider it proprietary. We disagree with their recommendations. The Table summarises international recommendations for administration of MMR/MMR-V vaccines to egg-allergic individuals.6,11,14-16 It is recommended that all patients, including those with suspected or confirmed egg allergy, should receive the MMR/MMR-V vaccination as a matter of routine in primary care, as the vaccine does not contain egg allergen.

Recommendations of the Hong Kong Institute of Allergy and the Hong Kong Society for Paediatric Immunology Allergy & Infectious Diseases

1. All patients with suspected or confirmed egg allergy should receive the MMR/MMR-V vaccination as a matter of routine in primary care.
### TABLE. Summary of international recommendations on administrating vaccines to egg-allergic individuals

<table>
<thead>
<tr>
<th>Authority (country)</th>
<th>Recommendations on administrating influenza vaccines to egg-allergic individuals</th>
<th>Recommendations on administrating MMR/MMR-V vaccines to egg-allergic individuals</th>
</tr>
</thead>
<tbody>
<tr>
<td>Australian Society of Clinical Immunology and Allergy</td>
<td>• Presence of egg allergy does not increase the risk of allergic reactions to the influenza vaccines.</td>
<td>• MMR vaccine is cultured on chicken fibroblast cell cultures, which contains no residual egg allergen and has been safely administered to large numbers of egg-allergic individuals.</td>
</tr>
<tr>
<td>(Australia)</td>
<td>• Entire vaccine can be administered in community vaccination clinics as a single dose followed by a 15-to-20-minute waiting period. A longer waiting period (30 minutes) may be warranted if there is significant parental or health professional anxiety.</td>
<td>• Rare allergic reactions have been attributed to non-egg ingredients such as gelatine.</td>
</tr>
<tr>
<td></td>
<td>• The immediate availability of a medical practitioner care is recommended and staff should be familiar with the recognition and treatment of anaphylaxis.</td>
<td>• MMR-V vaccine is considered not to contain food-derived protein allergens and can be given to any patient with food allergy, even those with food-induced anaphylaxis.</td>
</tr>
<tr>
<td></td>
<td>• Should there be anaphylaxis to influenza vaccine itself, further vaccination should be avoided without specialist allergy assessment.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• The following are not recommended:</td>
<td>• The vaccine ingredients extremely rarely cause anaphylactic reactions. Children should not get MMR-V vaccine if they have ever had a life-threatening allergic reaction to any component of the vaccine, including gelatine or the antibiotic neomycin.</td>
</tr>
<tr>
<td></td>
<td>o split dosing;</td>
<td>• No specific recommendations mentioned for egg-allergic individuals.</td>
</tr>
<tr>
<td></td>
<td>o allergy testing with the vaccine or egg prior to administration;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>o ingestion of egg as a pre-condition to administering the vaccine;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>o vaccination in specific hospital-based vaccination clinics;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>o allergy specialist review before influenza vaccination unless anaphylaxis to the influenza vaccine itself has occurred previously.</td>
<td></td>
</tr>
<tr>
<td>Centers for Disease Control and Prevention (US)</td>
<td>• Any licensed and recommended flu vaccines are recommended to egg-allergic individuals who have experienced urticaria only.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Egg-allergic individuals who had other symptoms such as angioedema, respiratory distress, light-headedness or recurrent enuresis, or who required epinephrine or another emergency medical intervention may receive any licensed and recommended flu vaccine. Flu vaccines should be administered in an in-patient or out-patient medical setting.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Vaccine administration should be supervised by a health care provider who is able to recognise and manage severe allergic conditions.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• A previous severe allergic reaction to flu vaccine, regardless of the component suspected of being responsible for the reaction, is a contra-indication to future receipt of the vaccine.</td>
<td></td>
</tr>
<tr>
<td>American Academy of Allergy Asthma and Immunology (US)</td>
<td>• Influenza vaccines should be administered to individuals with egg allergy of any severity, just as they would be to individuals without egg allergy.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• No special precautions beyond those recommended for the administration of any vaccine to any patient are necessary for administration of influenza vaccine to egg-allergic individuals.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Use of non-egg-based influenza vaccines, such as cciV3 or RIV3, in egg-allergic individuals in the age-groups for which they are approved is acceptable but not medically necessary or preferred.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Live attenuated influenza vaccine may be administered to egg-allergic patients of any severity in the age-group for which it is approved (age 2-49 years), in particular countries and seasons when live attenuated influenza vaccine is recommended as an agent (based on effectiveness in prior seasons).</td>
<td></td>
</tr>
<tr>
<td>American Academy of Pediatrics (US)</td>
<td>• Inactivated influenza vaccine administered in a single, age-appropriate dose is well tolerated by recipients with an egg allergy of any severity. Special precautions for egg-allergic recipients of inactivated influenza vaccine are not warranted, because the rate of anaphylaxis after inactivated influenza vaccine administration is no greater in egg-allergic than in non-egg allergic recipients from other universally recommended vaccines.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• All children with an egg allergy of any severity can receive an influenza vaccine without any additional precautions beyond those recommended for any vaccine.</td>
<td>• Measles vaccine is produced in chicken embryo cell culture and does not contain significant amounts of egg white (ovalbumin) cross-reacting proteins.</td>
</tr>
<tr>
<td></td>
<td>• Patients who refuse to receive an egg-based vaccine may be vaccinated with an age-appropriate recombinant or cell-culture product.</td>
<td>• Children with egg allergy are a low risk of anaphylactic reactions to measles-containing vaccines (including MMR and MMR-V).</td>
</tr>
<tr>
<td></td>
<td>• Quadrivalent live attenuated influenza vaccine is not recommended for use in any setting in the United States during the 2017-2018 influenza seasons.</td>
<td>• Skin testing of children for egg allergy is not predictive of reaction to MMR vaccine and is not recommended before administering MMR or other measles-containing vaccines.</td>
</tr>
</tbody>
</table>

Abbreviations: MMR = measles-mumps-rubella; MMR-V = measles-mumps-rubella-varicella; UK = United Kingdom; US = United States
5. **Egg-allergic individuals**

- Children with egg allergy can safely be vaccinated with Fluenz Tetra (AstraZeneca UK Ltd) in any setting.
- Children who have previously required admission to an intensive care unit for severe anaphylaxis to egg should be referred to a specialist for immunisation in hospital.
- Fluenz Tetra should not be administered to a child with current or recent acute wheezing in the 72 hours preceding vaccination, or who have required oral steroids in the previous 2 weeks.
- Facilities and staff trained to recognise and treat anaphylaxis should be available.

6. **Fluenz Tetra** in any setting.

- **World Allergy Organization**
  - Egg allergy does not appear to impart an increased risk of an anaphylactic reaction to immunisation with either inactivated or live attenuated influenza vaccines.
  - Immediate hypersensitivity reactions such as urticaria are no more common in egg-allergic than non-egg allergic vaccine recipients.
  - Any age-approved influenza vaccine can be used in any patient irrespective of egg allergy status and that special precautions are not required.

2. Influenza vaccines can be safely administered, and are recommended, for disease prevention in egg-allergic individuals. They are recommended to be administered in an out-patient or ambulatory setting.

3. Only those patients who have previously required admission to an intensive care unit for severe anaphylaxis to egg should be referred to an allergist for further evaluation prior to influenza vaccination.

4. Should there be any significant concerns from patients, parents or health care professionals, health care professionals who are capable of recognising signs and symptoms of an allergic reaction can provide 15 to 30 minutes of monitoring following vaccination.

5. Specialist evaluation is recommended prior to yellow fever vaccination in egg-allergic individuals (Fig).

6. Individuals who have developed or are suspected to have developed an allergic reaction to the vaccine or other vaccine components (such as gelatine or neomycin) should not undergo further vaccination with these products. Referral to an allergy specialist for further evaluation can be considered (Fig).

7. A significant number of suspected egg-allergic patients may be misdiagnosed, so referral to an allergist for evaluation may be considered.

**Author contributions**

GT Chua and PH Li drafted the main text of the article, including the tables and figures. E Lai and V Đặng offered their expert opinion as clinical pharmacists and contacted pharmaceutical companies regarding the contents of the vaccines. MHK Ho, MYW Kwan, FYS Yau, TF Leung, and TH Lee contributed to the concept, analysis, and critical revision of the article.

**Funding/support**

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

---

**TABLE. (cont’d)**

<table>
<thead>
<tr>
<th>Authority (country)</th>
<th>Recommendations on administering influenza vaccines to egg-allergic individuals</th>
<th>Recommendations on administering MMR/MMR-V vaccines to egg-allergic individuals</th>
</tr>
</thead>
</table>
| British Society for Allergy & Clinical Immunology (UK)\(^ {10,16}\) | - Children with egg allergy can safely be vaccinated with Fluenz Tetra (AstraZeneca UK Ltd) in any setting.  
- Children who have previously required admission to an intensive care unit for severe anaphylaxis to egg should be referred to a specialist for immunisation in hospital.  
- Fluenz Tetra should not be administered to a child with current or recent acute wheezing in the 72 hours preceding vaccination, or who have required oral steroids in the previous 2 weeks.  
- Facilities and staff trained to recognise and treat anaphylaxis should be available. | - Administration of the MMR vaccine to egg-allergic children has an excellent safety record and may be administered to all egg-allergic children as a routine procedure in primary care.  
- The MMR vaccine is grown on cultured-embryo-chick fibroblasts and is therefore generally free of hen’s egg protein.  
- When traces of hen’s egg protein are found, the protein is highly processed and the concentrations are too low to represent a risk. |
| World Allergy Organization\(^ {11}\) | - Egg allergy does not appear to impart an increased risk of an anaphylactic reaction to immunisation with either inactivated or live attenuated influenza vaccines.  
- Immediate hypersensitivity reactions such as urticaria are no more common in egg-allergic than non-egg allergic vaccine recipients.  
- Any age-approved influenza vaccine can be used in any patient irrespective of egg allergy status and that special precautions are not required. | - The manufacture of vaccines containing live virus produced in chick embryo cultures (measles and mumps) and human diploid cell culture (rubella) has resulted in a vaccine that contains no, or at most picogram quantities of egg protein, insufficient to cause an allergic reaction.  
- All children with egg allergy should receive the MMR vaccination as a routine procedure in primary care.  
- Anaphylactic reactions to MMR vaccine are not associated with hypersensitivity to egg antigens but to other components of the vaccine. |
| UK Department of Health–The Green Book\(^ {12}\) | Adults  
- The ovalbumin-free influenza vaccine, if available, can be used in any setting in patients from the age of 18 years, regardless of the severity of egg allergy.  
- Adult patients can also be immunised in any setting using an inactivated influenza vaccine with an ovalbumin content <0.12 µg/mL (equivalent to 0.06 µg for 0.5 mL dose), excluding those with severe anaphylaxis to egg that has previously required intensive care who should be referred to specialists for immunisation in hospital.  
- Children  
- Exception for those with severe anaphylaxis to egg that has previously required intensive care, children with an egg allergy can be safely vaccinated with Fluenz Tetra in any setting (including primary care and schools).  
- Those with clinical risk factors that contra-indicate Fluenz Tetra should be offered an inactivated influenza vaccine with a very low ovalbumin content (<0.12 µg/mL). |  

---

<table>
<thead>
<tr>
<th>Authority (country)</th>
<th>Recommendations on administering influenza vaccines to egg-allergic individuals</th>
<th>Recommendations on administering MMR/MMR-V vaccines to egg-allergic individuals</th>
</tr>
</thead>
</table>
| **British Society for Allergy & Clinical Immunology (UK)** | - Children with egg allergy can safely be vaccinated with Fluenz Tetra (AstraZeneca UK Ltd) in any setting.  
- Children who have previously required admission to an intensive care unit for severe anaphylaxis to egg should be referred to a specialist for immunisation in hospital.  
- Fluenz Tetra should not be administered to a child with current or recent acute wheezing in the 72 hours preceding vaccination, or who have required oral steroids in the previous 2 weeks.  
- Facilities and staff trained to recognise and treat anaphylaxis should be available. | - Administration of the MMR vaccine to egg-allergic children has an excellent safety record and may be administered to all egg-allergic children as a routine procedure in primary care.  
- The MMR vaccine is grown on cultured-embryo-chick fibroblasts and is therefore generally free of hen’s egg protein.  
- When traces of hen’s egg protein are found, the protein is highly processed and the concentrations are too low to represent a risk. |
| **World Allergy Organization** | - Egg allergy does not appear to impart an increased risk of an anaphylactic reaction to immunisation with either inactivated or live attenuated influenza vaccines.  
- Immediate hypersensitivity reactions such as urticaria are no more common in egg-allergic than non-egg allergic vaccine recipients.  
- Any age-approved influenza vaccine can be used in any patient irrespective of egg allergy status and that special precautions are not required. | - The manufacture of vaccines containing live virus produced in chick embryo cultures (measles and mumps) and human diploid cell culture (rubella) has resulted in a vaccine that contains no, or at most picogram quantities of egg protein, insufficient to cause an allergic reaction.  
- All children with egg allergy should receive the MMR vaccination as a routine procedure in primary care.  
- Anaphylactic reactions to MMR vaccine are not associated with hypersensitivity to egg antigens but to other components of the vaccine. |
| **UK Department of Health–The Green Book** | Adults  
- The ovalbumin-free influenza vaccine, if available, can be used in any setting in patients from the age of 18 years, regardless of the severity of egg allergy.  
- Adult patients can also be immunised in any setting using an inactivated influenza vaccine with an ovalbumin content <0.12 µg/mL (equivalent to 0.06 µg for 0.5 mL dose), excluding those with severe anaphylaxis to egg that has previously required intensive care who should be referred to specialists for immunisation in hospital.  
- Children  
- Exception for those with severe anaphylaxis to egg that has previously required intensive care, children with an egg allergy can be safely vaccinated with Fluenz Tetra in any setting (including primary care and schools).  
- Those with clinical risk factors that contra-indicate Fluenz Tetra should be offered an inactivated influenza vaccine with a very low ovalbumin content (<0.12 µg/mL). |  

---
Patient with suspected egg allergy requiring vaccination

History of reaction to previous vaccine or vaccine components

No

MMR/MMR-V vaccine

Influenza vaccine

Yellow fever vaccine

History of anaphylaxis to egg with ICU admission

Yes

Genuine egg allergy

No

Vaccination as routine in primary care

Yes

Specialist referral

FIG. Proposed workflow for vaccinating patients with suspected egg allergy

Abbreviations: ICU = intensive care unit; MMR = measles-mumps-rubella; MMR-V = measles-mumps-rubella-varicella

Declaration

All authors have disclosed no conflicts of interest. All authors had full access to the data, contributed to the study, approved the final version for publication, and take responsibility for its accuracy and integrity.

References